Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing
NCT ID: NCT06861036
Last Updated: 2025-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
50 participants
INTERVENTIONAL
2025-05-15
2028-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO)
NCT06425146
Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity
NCT05791149
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma
NCT03759730
Liquid Biopsy in Head and Neck Cancer
NCT03926468
Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma
NCT05821179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OSCC treatment is based on surgery and/or radiotherapy and/or chemotherapy. Immune Check point Inhibitors (ICIs) targeting PD-1 have been approved for recurrent and metastasic OSCC. However, only 15-20% of these patients are treated thanks to this anti-PD-1. Thus, there is a real need to improve the efficacy of ICIs in the treatment of HNSCC. The scRNAseq is a method which allows to study the tumoral heterogeneity, the microenvironment and the dynamic and regulation mecanisms in cells cancer. This technology could improve patient stratification, identify pronostic biomarkers, constitute an important tool in the therapeutical take care and lead to understand tumoral evolution and develop new prevention strategies.
The aim of the study is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scRNAseq in OSCC patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
Samples:
* 1 blood sample (6 mL)
* 1 or 2 tumoral specimen (depending on the size of the tumor)
* 1 specimen of the healthy oral mucosa
* 1 leucoplakia specimen if applicable. The biospecimens will be collected at the time of the surgery scheduled in the standard routine medical care.
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clinical-biological cohort
A clinical-biological cohort of 50 patients with OSCC.
Blood sample and biospecimen at the time of a standard surgery.
Biospecimen
* 1 or 2 tumoral specimen (depending on the size of the tumor)
* 1 specimen of the healthy oral mucosa
* 1 leucoplakia specimen if applicable.
The biospecimens will be collected at the time of the surgery organised for the standard routine medical care.
Blood sampling
Blood sampling (6 mL), taken from a routine biological exam.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biospecimen
* 1 or 2 tumoral specimen (depending on the size of the tumor)
* 1 specimen of the healthy oral mucosa
* 1 leucoplakia specimen if applicable.
The biospecimens will be collected at the time of the surgery organised for the standard routine medical care.
Blood sampling
Blood sampling (6 mL), taken from a routine biological exam.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* I2. Patient with OSCC and undergoing surgery at the Centre Léon Bérard.
* I3. Patient who has agreed to participate in this research and sign consent.
* I4. Patient affiliated to a medical insurance.
Exclusion Criteria
* NI2. Contraindication to general anesthesia.
* NI3. Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...).
* NI4. Patient under curatorial or guardianship or placed under the protection of justice.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Leon Berard
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Léon Bérard
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ET22-338 HOASIS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.